期刊
CANCER JOURNAL
卷 27, 期 1, 页码 25-31出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0000000000000501
关键词
Biomarkers; immunology; TNBC; triple-negative breast cancer; tumor-infiltrating lymphocytes
类别
资金
- Merck
- Puma Biotechnology
- Roche
- Novartis
- Bristol Meyers Squibb
- Roche-Genentech
- Pfizer
- Eli Lilly
- Nektar Therapeutics
- Astra Zeneca
- Seattle Genetics
- Breast Cancer Research Foundation (BCRF) [17-194]
- Breast Cancer Research Foundation (BCRF) NYand the National Breast Cancer Foundation (NBCF) of Australia
Triple-negative breast cancer (TNBC) has poorer outcomes compared to other subtypes, and there is a lack of established treatment options beyond chemotherapy. Biomarkers are needed to improve prognosis and guide therapy, with tumor-infiltrating lymphocytes gaining relevance as an immunological biomarker in this field.
Triple-negative breast cancer (TNBC) continues to represent an unmet need because of its significantly poorer outcomes, including higher relapse rates following early-stage disease and dismal survival times in the advanced setting, when compared with other breast cancer subtypes (Cancer 2012;118:5463-5472). Furthermore, there remains a lack of established systemic treatment options beyond conventional cytotoxic chemotherapy, with the exception of PARP inhibitors in the small subset of patients who harbor a BRCA mutation (N Engl J Med 2018;379:753; Lancet Oncol 2020;21:1269-1282; Ann Oncol 2019;30:558-566) and recently the use of immunotherapy in the first-line metastatic setting in those who are programmed death ligand 1-positive (Lancet Oncol 2020;21(1):44-59; N Engl J Med 2018;379(22):2108-2121). Suitable biomarkers for improving prognostication and directing therapy in both the early and advanced TNBC settings are required in order for improvements in survival outcomes to be continued to be attained. Tumor-infiltrating lymphocytes are gaining increasing relevance as an immunological biomarker in this arena.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据